The Relevance of a Novel Quantitative Assay to Detect up to 40 Major Streptococcus pneumoniae Serotypes Directly in Clinical Nasopharyngeal and Blood Specimens
Subject: Infectious disease
Some researchers of our research team have published an article on the relevance of a novel quantitative essay to detect up to 40 major streptococcus pneumoniae serotypes directly in clinical nasophraryngeal and blood specimens.
Mélina Messaoudi and Milen Milenkov have worked on this research project. Mélina MESSAOUDI developed the test in 2009 and export the assay in the GABRIEL network in the frame of the multicentric study for pneumonia ended late 2014. Milen MILENKOV improved the assay since his arrival early 2011 and developed the quantitative part of the assay. Their research took place in the Emerging Pathogens Laboratory, Fondation Mérieux, Lyon.The work was supervised by Glaucia Baccala.
Mélina Messaoudi biosketch
Mélina Messaoudi joined the Emerging Pathogens Laboratory in May 2008 to work on the development of a DNA chip using Affymetrix technology for the detection, the typing and the subtyping and the characterization of influenza virus. Afterward, she worked on the development of a multiplex real time PCR to type and to quantify the 40 most prevalent Streptococcus pneumoniae serotypes/serogroups and transferred the method in developing countries. She worked for 2 years on a multicentric study for the pneumonia etiology in children under 5 years old. She is now working on the development of a molecular typing test for the 40 most prevalent Streptococcus pneumoniae serotypes/serogroups using the xMAP technology from Luminex®.
She obtained a Master's in Biochemistry and Biotechnology Engineering in January 2008 from the Claude Bernard University of Lyon. She worked at bioMérieux within the R&D Immunoassay Department on the evaluation of stroke's biomarkers using the ELISA technique (microplates, silica beads and VIDAS system).